FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1316-1324 May 4, 2000 Number 18 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background When administered intravenously at the time of percutaneous coronary revascularization, glycoprotein IIb/IIIa receptor antagonists decrease the incidence of death and nonfatal myocardial infarction and the need for urgent revascularization. We hypothesized that long-term administration of oral glycoprotein IIb/IIIa antagonists, which block the aggregation of platelets, might stabilize intravascular plaque and prevent additional ischemic cardiac events.

Methods We conducted a prospective, double-blind trial in which 7232 patients were randomly assigned to receive 20 mg of oral xemilofiban or placebo 30 to 90 minutes before undergoing percutaneous coronary revascularization, with maintenance doses of 10 or 20 mg of xemilofiban or placebo administered three times daily for up to 182 days. There were two primary composite end points: one was death, nonfatal myocardial infarction, or urgent revascularization at 182 days, and the other was death or nonfatal myocardial infarction at 182 days.

Results Death, myocardial infarction, or urgent revascularization occurred within 182 days in 324 patients who received placebo (Kaplan–Meier cumulative event rate, 13.5 percent), 332 who received 10 mg of xemilofiban (13.9 percent, P=0.82 for the comparison with placebo), and 306 who received 20 mg of xemilofiban (12.7 percent, P=0.36 for the comparison with placebo). The incidence of death or myocardial infarction was also similar in all three groups. Clinically significant hemorrhagic complications and thrombocytopenia were infrequent.

Conclusions The administration of the glycoprotein IIb/IIIa antagonist xemilofiban before percutaneous coronary revascularization and for up to six months thereafter does not significantly reduce the incidence of important clinical end points.

Source Information

From the Division of Cardiology, William Beaumont Hospital, Royal Oak, Mich. (W.W.O., G.C.T.); Thoraxcenter, Rotterdam, the Netherlands (P.S., C.Z.); Foothills Hospital, Calgary, Alta., Canada (M.K.); Cardialysis, Rotterdam, the Netherlands (G.-A.E.); G.D. Searle, Skokie, Ill. (J.K., J.G., J.A., R.A.); the University of Wisconsin, Madison (E.B.R.); and the Corvallis Clinic, Corvallis, Oreg. (R.D.).

Address reprint requests to Dr. O'Neill at the Division of Cardiology, William Beaumont Hospital, 3601 W. 13 Mile Rd., Royal Oak, MI 48073, or at woneill{at}beaumont.edu.

Full Text of this Article

This article has been cited by other articles:

• Marin, F., Gonzalez-Conejero, R., Capranzano, P., Bass, T. A., Roldan, V., Angiolillo, D. J. (2009). Pharmacogenetics in cardiovascular antithrombotic therapy.. J Am Coll Cardiol 54: 1041-1057 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Meadows, T. A., Bhatt, D. L. (2007). Clinical Aspects of Platelet Inhibitors and Thrombus Formation. Circ. Res. 100: 1261-1275 [Abstract] [Full Text]  
• (2006). Additional Information. JAMA 295: E1-E6 [Full Text]  
• Marx, N., Wohrle, J., Nusser, T., Walcher, D., Rinker, A., Hombach, V., Koenig, W., Hoher, M. (2005). Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients. Circulation 112: 2792-2798 [Abstract] [Full Text]  
• Freedman, J. E. (2005). Molecular Regulation of Platelet-Dependent Thrombosis. Circulation 112: 2725-2734 [Abstract] [Full Text]  
• Armstrong, P. W., Newby, L. K., Granger, C. B., Lee, K. L., Simes, R. J., Van de Werf, F., White, H. D., Califf, R. M., for the Virtual Coordinating Centre for Global Col, (2004). Lessons Learned From a Clinical Trial. Circulation 110: 3610-3614 [Full Text]  
• Lemos, P. A., Mercado, N., van Domburg, R. T., Kuntz, R. E., O'Neill, W. W., Serruys, P. W. (2004). Comparison of Late Luminal Loss Response Pattern After Sirolimus-Eluting Stent Implantation or Conventional Stenting. Circulation 110: 3199-3205 [Abstract] [Full Text]  
• Choi, D., Kim, S.-K., Choi, S.-H., Ko, Y.-G., Ahn, C.-W., Jang, Y., Lim, S.-K., Lee, H.-C., Cha, B.-S. (2004). Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. Diabetes Care 27: 2654-2660 [Abstract] [Full Text]  
• Beatt, K J, Morgan, K P, Kapur, A (2004). Revascularisation in diabetics with multivessel coronary artery disease. Heart 90: 999-1002 [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Vishnevetsky, D., Kiyanista, V. A, Gandhi, P. J (2004). CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease. The Annals of Pharmacotherapy 38: 1500-1508 [Abstract] [Full Text]  
• Viles-Gonzalez, J. F, Fuster, V., Badimon, J. J (2004). Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J 25: 1197-1207 [Abstract] [Full Text]  
• West, N. E.J., Ruygrok, P. N., Disco, C. M.C., Webster, M. W.I., Lindeboom, W. K., O'Neill, W. W., Mercado, N. F., Serruys, P. W. (2004). Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients. Circulation 109: 867-873 [Abstract] [Full Text]  
• Qureshi, M. A., Safian, R. D., Grines, C. L., Goldstein, J. A., Westveer, D. C., Glazier, S., Balasubramanian, M., O'Neill, W. W. (2003). Simplified scoring system for predicting mortality after percutaneous coronary intervention. J Am Coll Cardiol 42: 1890-1895 [Abstract] [Full Text]  
• Knight, C. J (2003). Antiplatelet treatment in stable coronary artery disease. Heart 89: 1273-1278 [Full Text]  
• Topol, E. J., Easton, D., Harrington, R. A., Amarenco, P., Califf, R. M., Graffagnino, C., Davis, S., Diener, H.-C., Ferguson, J., Fitzgerald, D., Granett, J., Shuaib, A., Koudstaal, P. J., Theroux, P., Van de Werf, F., Sigmon, K., Pieper, K., Vallee, M., Willerson, J. T. (2003). Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease. Circulation 108: 399-406 [Abstract] [Full Text]  
• Mercado, N, Maier, W, Boersma, E, Bucher, C, de Valk, V, O'Neill, W.W, Gersh, B.J, Meier, B, Serruys, P.W, Wijns, W (2003). Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting: Implications for mechanical plaque sealing. Eur Heart J 24: 541-551 [Abstract] [Full Text]  
• Mehta, S. R., Yusuf, S. (2003). Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 41: 79S-88S [Abstract] [Full Text]  
• Muckian, C., Fitzgerald, A., O'Neill, A., O'Byrne, A., Fitzgerald, D. J., Shields, D. C. (2002). Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. Blood 100: 1220-1223 [Abstract] [Full Text]  
• Quinn, M. J., Plow, E. F., Topol, E. J. (2002). Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?. Circulation 106: 379-385 [Full Text]  
• Leebeek, F.W.G., Boersma, E., Cannon, C.P., van de Werf, F.J.J., Simoons, M.L. (2002). Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J 23: 444-457 [Full Text]  
• O'Connor, F. F., Shields, D. C., Fitzgerald, A., Cannon, C. P., Braunwald, E., Fitzgerald, D. J. (2001). Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 98: 3256-3260 [Abstract] [Full Text]  
• Batchelor, W. B., Mahaffey, K. W., Berger, P. B., Deutsch, E., Meier, S., Hasselblad, V., Fry, E. T., Teirstein, P. S., Ross, A. M., Binanay, C. A., Zidar, J. P., the ATLAST Trial Investigators, (2001). A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 38: 1608-1613 [Abstract] [Full Text]  
• Frelinger, A. L. III, Furman, M. I., Krueger, L. A., Barnard, M. R., Michelson, A. D. (2001). Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation. Circulation 104: 1374-1379 [Abstract] [Full Text]  
• (2001). Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes. Circulation 103: 1727-1733 [Abstract] [Full Text]  
• Agnelli, G. (2001). Rationale for the use of platelet aggregation inhibitors in PAD patients. Vasc Med 6: 13-15 [Abstract]  
• Chew, D. P., Bhatt, D. L., Sapp, S., Topol, E. J. (2001). Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists : A Meta-Analysis of Phase III Multicenter Randomized Trials. Circulation 103: 201-206 [Abstract] [Full Text]  
• Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G. (2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest 119 : 39S-63S [Full Text]  
• Curtin, R., Fitzgerald, D.J. (2000). A cold start for oral glycoprotein IIb/IIIa antagonists. Eur Heart J 21: 1992-1994  
• Akkerhuis, K. M., Neuhaus, K.-L., Wilcox, R. G., Vahanian, A., Boland, J.-L., Hoffmann, J., Baardman, T., Nehmiz, G., Roth, U., Klootwijk, A. P. J., Deckers, J. W., Simoons, M. L., Fibrinogen Receptor Occupancy STudy Investigators, (2000). Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study. Eur Heart J 21: 2042-2055 [Abstract]  
• Chew, D. P., Moliterno, D. J. (2000). A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 36: 2028-2035 [Abstract] [Full Text]  
• Quinn, M. J., Cox, D., Foley, J. B., Fitzgerald, D. J. (2000). Glycoprotein IIb/IIIa Receptor Number and Occupancy during Chronic Administration of an Oral Antagonist. J. Pharmacol. Exp. Ther. 295: 670-676 [Abstract] [Full Text]  
• Bhatt, D. L., Topol, E. J. (2000). Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA 284: 1549-1558 [Abstract] [Full Text]  
• Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., Pepine, C. J., Schaeffer, J. W., Smith, E. E. III, Steward, D. E., Theroux, P., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Faxon, D. P., Fuster, V., Gardner, T. J., Gregoratos, G., Russell, R. O., Smith, S. C. Jr (2000). ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 36: 970-1062 [Full Text]  
• (2000). Oral Glycoprotein IIb/IIIa Not Effective After PTCR. Journal Watch Cardiology 2000: 8-8 [Full Text]  
• Cannon, C. P., McCabe, C. H., Wilcox, R. G., Langer, A., Caspi, A., Berink, P., Lopez-Sendon, J., Toman, J., Charlesworth, A., Anders, R. J., Alexander, J. C., Skene, A., Braunwald, E. (2000). Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. Circulation 102: 149-156 [Abstract] [Full Text]  
• Bussel, J. B., Kunicki, T. J., Michelson, A. D. (2000). Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. ASH Education Book 2000: 222-240 [Abstract] [Full Text]